

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any other state securities law in the United States, and may not be offered or sold within the United States unless registered under the U.S. Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration under the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States. This announcement and the information contained herein are not for distribution, directly or indirectly, in or into the United States.



ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

Sole Overall Coordinator and Placing Agent

Jefferies

PLACING OF EXISTING SHARES

AND

TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

**PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES
UNDER GENERAL MANDATE**

On February 3, 2023, the Company, the Top-up Vendor and the Placing Agent entered into the Placing and Subscription Agreement, pursuant to which, (i) the Top-up Vendor agreed to sell, and the Placing Agent agreed, as agent of the Top-up Vendor, to procure on a best effort basis purchasers to purchase, 25,000,000 Placing Shares held by the Top-up Vendor at a price of HK\$15.22 per Placing Share; and (ii) the Top-up Vendor conditionally agreed to subscribe for, and the Company conditionally agreed to issue, 25,000,000 Subscription Shares at the Subscription Price, which is equivalent to the Placing Price.

It is expected that the Placing Shares will be placed by the Placing Agent to not less than six professional, institutional and/or individual investors who, together with their respective ultimate beneficial owners, are third parties independent of and not connected with the Top-up Vendor, the parties acting in concert with the Top-up Vendor, the Company and connected persons of the Company. It is not expected that any such investor will become a substantial shareholder of the Company as a result of the Vendor Placing.

The closing of the Vendor Placing is conditional upon fulfillment of the following conditions: (i) the customary termination events as set out in the Placing and Subscription Agreement not having occurred before the closing of the Vendor Placing; (ii) the representations and warranties made by any of the Company and the Top-up Vendor pursuant to the Placing and Subscription Agreement being true and accurate and not misleading as of the date of the Placing and Subscription Agreement and the Placing Closing Date; and (iii) each of the Company and the Top-up Vendor having complied with all of the agreements and undertakings and satisfied all of the conditions on its part to be complied with or satisfied under the Placing and Subscription Agreement on or before the Placing Closing Date.

The Subscription Shares will be allotted and issued under the General Mandate granted to the Directors pursuant to the ordinary resolution passed at the annual general meeting of the Company held on June 10, 2022. Under the General Mandate, a maximum of 187,846,347 Shares, representing 20% of the total number of Shares of the Company in issue as at June 10, 2022, may be allotted and issued by the Company. The Company has not issued any Shares pursuant to the General Mandate as at the date of this announcement.

Application will be made by the Company to the Stock Exchange for approval for the listing of, and permission to deal in, the Subscription Shares.

As the completion of the Vendor Placing and the Subscription is subject to the satisfaction of certain conditions precedent, it may or may not materialize as contemplated or at all, the Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

PLACING OF EXISTING SHARES AND SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

On February 3, 2023, the Company, the Top-up Vendor and the Placing Agent entered into the Placing and Subscription Agreement, pursuant to which, (i) the Top-up Vendor agreed to sell, and the Placing Agent agreed, as agent of the Top-up Vendor, to procure on a best effort basis purchasers to purchase, 25,000,000 Placing Shares held by the Top-up Vendor at a price of HK\$15.22 per Placing Share; and (ii) the Top-up Vendor conditionally agreed to subscribe for, and the Company conditionally agreed to issue, 25,000,000 Subscription Shares at the Subscription Price, which is equivalent to the Placing Price.

The principal terms of the Placing Agreement are summarized below:

THE PLACING AND SUBSCRIPTION AGREEMENT

Date

February 3, 2023

Parties

- (1) the Company;
- (2) Rubymab Ltd. as the Top-up Vendor; and
- (3) Jefferies Hong Kong Limited as the Placing Agent.

Vendor Placing

Placing Shares

The total number of Placing Shares is 25,000,000 Shares, representing approximately 2.7% of the issued share capital of the Company as of the date of this announcement and approximately 2.6% of the issued share capital of the Company as enlarged by the Subscription (assuming that there is no change in the issued share capital of the Company from the date of this announcement to the completion of the Vendor Placing and the Subscription save for the issue of the Subscription Shares). The aggregate nominal value of the Placing Shares is HK\$380.5 million.

Placing Price

The Placing Price of HK\$15.22 per Placing Share represents:

- (1) a discount of approximately 9.5% to the closing price of HK\$16.82 per Share as quoted on the Stock Exchange on the Last Trading Day;
- (2) a premium of approximately 7.1% to the average closing price of approximately HK\$14.208 per Share as quoted on the Stock Exchange for the last five (5) consecutive trading days prior to and including the Last Trading Day; and
- (3) a premium of approximately 12.7% to the average closing price of approximately HK\$13.504 per Share as quoted on the Stock Exchange for the last ten (10) consecutive trading days prior to and including the Last Trading Day.

The Placing Price of HK\$15.22 per Placing Share was arrived at after arm's length negotiations among the Company, the Top-up Vendor and the Placing Agent with reference to the market condition and the recent closing prices per Share.

Rights of the Placing Shares

The Placing Shares will be sold free of all liens, charges and other encumbrances, third party rights or other claims binding upon the Top-up Vendor and have the same rights as, and rank *pari passu* with, all of the other Shares of the same class.

Independence of the Placing Agent and Placees

To the best of the Director's knowledge, information and belief, having made all reasonable enquiries, the Placing Agent and its ultimate beneficial owner(s) are third parties independent of, and not connected with, the Company and its connected persons.

It is expected that the Placing Shares will be placed by the Placing Agent to not less than six professional, institutional and/or individual investors who, together with their respective ultimate beneficial owners, are third parties independent of and not connected with the Top-up Vendor, the Company and connected persons of the Company. It is not expected that any such investor will become a substantial shareholder of the Company as a result of the Vendor Placing.

Closing of the Vendor Placing

The closing of the Vendor Placing shall take place on the second business day after the date of the Placing and Subscription Agreement or at such other time and/or date as the Top-up Vendor and the Placing Agent may agree.

Conditions of the Vendor Placing

The closing of the Vendor Placing is conditional upon fulfillment of the following conditions: (i) the customary termination events as set out in the Placing and Subscription Agreement not having occurred before the closing of the Vendor Placing; (ii) the representations and warranties made by any of the Company and the Top-up Vendor pursuant to the Placing and Subscription Agreement being true and accurate and not misleading as of the date of the Placing and Subscription Agreement and the Placing Closing Date; and (iii) each of the Company and the Top-up Vendor having complied with all of the agreements and undertakings and satisfied all of the conditions on its part to be complied with or satisfied under the Placing and Subscription Agreement on or before the Placing Closing Date.

Subscription

Subscriber

The Top-up Vendor

Issuer

The Company

Subscription Shares

The number of Subscription Shares is 25,000,000 Shares in aggregate, representing approximately 2.7% of the issued share capital of the Company as of the date of this announcement and approximately 2.6% of the issued share capital of the Company as enlarged by the Subscription (assuming that there is no change in the issued share capital of the Company from the date of this announcement to the completion of the Vendor Placing and the Subscription save for the issue of the Subscription Shares). The number of Subscription Shares is equivalent to the number of the Placing Shares.

Subscription Price

The Subscription Price is equivalent to the Placing Price. The net share price for the Subscription is estimated to be approximately HK\$15.22 per Subscription Share.

General Mandate

The Subscription Shares will be allotted and issued under the General Mandate granted to the Directors pursuant to the ordinary resolution passed at the annual general meeting of the Company held on June 10, 2022. Under the General Mandate, a maximum of 187,846,347 Shares, representing 20% of the total number of Shares of the Company in issue as at June 10, 2022, may be allotted and issued by the Company. The Company has not issued any Shares pursuant to the General Mandate as at the date of this announcement.

As such, no further approval from Shareholders is required for the allotment and issue of the Subscription Shares.

Ranking of the Subscription Shares

The Subscription Shares shall, when fully paid, rank *pari passu* in all respects with the other Shares in issue or to be issued by the Company on or prior to the date of completion of the Subscription including the rights to all dividends and other distributions declared, made or paid on or after the date of allotment.

Conditions of the Subscription

The closing of the Subscription is conditional upon the fulfilment of the following conditions:

- (1) the Listing Committee of the Stock Exchange granting the listing of and permission to deal in the Subscription Shares and such listing and permission not subsequently revoked prior to the delivery of definitive share certificate(s) representing the Subscription Shares; and
- (2) the closing of the Vendor Placing having occurred pursuant to the terms of the Placing and Subscription Agreement.

Closing of the Subscription

The closing of the Subscription shall take place on the second business day after the date upon which the last of the conditions to completion of the Subscription to be satisfied shall have been so satisfied provided that it shall take place on a date no later than 14 days after the date of the Placing and Subscription Agreement, or at such other time and/or date as the Company, the Top-up Vendor and the Placing Agent may agree in writing and in compliance with the Listing Rules. In the event that the conditions are not fulfilled within 14 days following the date of the Placing and Subscription Agreement (or such later date as may be agreed among the Company, the Top-up Vendor and the Placing Agent), the obligations and liabilities of the Top-up Vendor and the Company under the Subscription shall be null and void and neither the Company nor the Top-up Vendor shall have any claim against the other for costs, damages, compensation or otherwise. Notwithstanding any provisions contained in the Placing and Subscription Agreement, the Placing Agent shall not be liable whatsoever in connection with the Subscription.

As the Top-up Vendor is a controlling shareholder and thus a connected person of the Company, the Subscription constitutes a connected transaction of the Company. If the Subscription is not completed within 14 days after the date of the Placing and Subscription Agreement, the Subscription will not be exempt from, among others, the independent Shareholders' approval requirement under Chapter 14A of the Listing Rules, unless otherwise waived by the Stock Exchange. Further announcement will be made by the Company if this occurs.

Application for Listing

Application will be made by the Company to the Stock Exchange for approval for the listing of, and permission to deal in, the Subscription Shares.

LOCK-UP UNDERTAKINGS BY THE TOP-UP VENDOR AND THE COMPANY

The Top-up Vendor has undertaken to the Placing Agent that it shall not, and shall procure that none of its nominees, any person controlled by it, any trust associated with it or any person acting on its or their behalf shall, without the prior written consent of the Placing Agent, (i) offer, sell, lend, contract to sell, pledge, grant any option over, make any short sale or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the Top-up Vendor or any Affiliate of the Top-up Vendor or any person in privity with the Top-up Vendor or any Affiliate of the Top-up Vendor), directly or indirectly, any equity securities of the Company or any securities convertible into, or exercisable, or exchangeable for, equity securities of the Company, (ii) enter into any swap or similar agreement that transfers, in whole or in part, the economic risk of ownership of such Shares, whether any such transaction described in (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or otherwise, or (iii) publicly announce an intention to effect any such transaction, for a period beginning on the date of the Placing and Subscription Agreement and ending on the date which is 90 days after the Placing Closing Date. The foregoing shall not apply to the Vendor Placing under the Placing and Subscription Agreement.

The Company has undertaken to the Placing Agent that it, and the Top-up Vendor undertakes to the Placing Agent that it shall procure the Company that the Company, will not, without the prior written consent of the Placing Agent, (i) effect or arrange or procure placement of, allot or issue or offer to allot or issue or grant any option, right or warrant to subscribe for, or enter into any transaction which is designed to, or might reasonably be expected to, result in any of the aforesaid (whether by actual disposition or effective economic disposition due to cash settlement or otherwise), directly or indirectly, any equity securities of the Company or any securities convertible into, or exercisable, or exchangeable for, equity securities of the Company, or (ii) enter into any swap or similar agreement that transfers, in whole or in part, the economic risk of ownership of such Shares, whether any such transaction described in (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or otherwise, or (iii) publicly announce an intention to effect any such transaction, for a period beginning on the date of the Placing and Subscription Agreement and ending on the date which is 90 days after the Placing Closing Date. The foregoing shall not apply to the issue of the Subscription Shares under the Placing and Subscription Agreement.

USE OF PROCEEDS

The gross proceeds from the Subscription are expected to be approximately HK\$380.5 million. The net proceeds from the Subscription are estimated to be approximately HK\$376.2 million, net of all applicable costs and expenses including commissions, professional fees and out-of pocket expenses. The Company intends to apply (i) approximately 80% of net proceeds to be received to launch several registered clinical trials of JSKN003, one of the Company's key products, for the treatment of solid tumors e.g. breast cancer and gastric cancer with human epidermal growth factor receptor 2 low/high expressions, (ii) approximately 10% of the net proceeds to be received to the clinical development of JSKN016, one key candidate product of the Company, and (iii) approximately 10% of the net proceeds to be received for the Company's general corporate purposes.

REASONS FOR THE VENDOR PLACING AND THE SUBSCRIPTION

The Vendor Placing and the Subscription are beneficial to continuously developing the Company's pipeline of candidate antibody-drug conjugates whilst broadening the shareholder base of the Company. The Directors consider that the Vendor Placing and the Subscription will also provide an opportunity to further strengthen the Company's financial position and provide additional working capital to the Company.

The Directors are of the view that the terms of the Placing and Subscription Agreement, including the Placing Price and the Subscription Price, are fair and reasonable and believe that the Vendor Placing and the Subscription are in the best interests of the Company and the Shareholders as a whole.

As the completion of the Vendor Placing and the Subscription is subject to the satisfaction of certain conditions precedent, it may or may not materialize as contemplated or at all, the Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

EFFECT ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

The shareholding structure of the Company immediately before and immediately after the Vendor Placing and the Subscription will be as follows:

Shareholder	As of the date of this announcement		Immediately after completion of the Vendor Placing but before completion of the Subscription		Immediately after completion of the Vendor Placing and the Subscription	
	<i>Number of Shares</i>	<i>Approximately %</i>	<i>Number of Shares</i>	<i>Approximately %</i>	<i>Number of Shares</i>	<i>Approximately %</i>
Top-up Vendor	314,000,000	33.41	289,000,000	30.75	314,000,000	32.55
Placees	—	—	25,000,000	2.66	25,000,000	2.59
Other Shareholders	<u>625,716,387</u>	<u>66.59</u>	<u>625,716,387</u>	<u>66.59</u>	<u>625,716,387</u>	<u>64.86</u>
Total	<u>939,716,387</u>	<u>100.00</u>	<u>939,716,387</u>	<u>100.00</u>	<u>964,716,387</u>	<u>100.00</u>

The Directors confirm that, immediately after closing of the Vendor Placing and the Subscription, the public float of the Company will be no less than 25% of the Company's issued share capital as enlarged by the Subscription (assuming there is no change in the issued share capital of the Company from the date of this announcement to the completion of the Vendor Placing and the Subscription save for the issue of the Subscription Shares).

FUND RAISING ACTIVITIES IN THE PAST 12 MONTHS

The Company has not conducted any fund-raising activity involving issuing equity securities during the 12 months immediately before the date of this announcement.

INFORMATION ABOUT THE GROUP AND THE TOP-UP VENDOR

The Company is a leading biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecific and protein engineering. Differentiated in-house clinical pipeline of the Company includes the oncology drug candidates with one approved for marketing by the National Medical Products Administration of China (國家藥品監督管理局), three in late clinical stage and two in phase I clinical trial stage.

The Top-up Vendor is a company incorporated in the British Virgin Islands on March 22, 2018 and wholly owned by a discretionary family trust established by Dr. XU as settlor for the benefits of Dr. XU's family members, of which South Dakota Trust Company LLC is a trustee.

DEFINITIONS

In this announcement, unless it is defined or the context requires otherwise, the following terms shall have the following meanings:

“Affiliate” has the meaning specified in Rule 501(b) of Regulation D under the U.S. Securities Act

“Board” the board of the Directors

“Company”	Alphamab Oncology (康寧傑瑞生物製藥), an exempted company with limited liability incorporated under the laws of the Cayman Islands on March 28, 2018, the share of which are listed on the Stock Exchange (stock code: 9966)
“Director(s)”	the director(s) of the Company
“Dr. XU”	Dr. XU Ting (徐霆), the founder, chairman, executive Director and chief executive officer of the Company
“General Mandate”	the general mandate granted to the Directors by a resolution of the Shareholders passed at the annual general meeting of the Company held on June 10, 2022 to allot, issue and otherwise deal with securities of the Company not exceeding 20% of the total number of Shares in issue as of June 10, 2022
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Last Trading Day”	February 2, 2023, being the last trading day prior to the signing of the Placing Agreement
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Placing Agent”	Jefferies Hong Kong Limited
“Placing and Subscription Agreement”	the placing and subscription agreement entered into among the Company, the Top-up Vendor and the Placing Agent in relation to the Vendor Placing and the Subscription on February 3, 2023
“Placing Closing Date”	the closing date of the Vendor Placing
“Placing Price”	HK\$15.22 per Placing Share
“Placing Shares”	25,000,000 Shares currently owned by the Top-up Vendor and to be placed by the Placing Agent pursuant to the Placing and Subscription Agreement
“PRC” or “China”	the People’s Republic of China which, for the purpose of this announcement, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan

“Share(s)”	share(s) of par value of US\$0.000002 each in the issued share capital of the Company
“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subscription”	the subscription of the Subscription Shares by the Top-up Vendor pursuant to the Placing and Subscription Agreement
“Subscription Price”	HK\$15.22 per Share, which is equal to the Placing Price
“Top-up Vendor”	Rubymab Ltd., being a Shareholder interested in 314,000,000 Shares, representing approximately 33.41% of the existing issued share capital of the Company as at the date of this announcement
“United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“US\$”	United States dollars, the lawful currency of the United States
“Vendor Placing”	the placing of 25,000,000 existing Shares by the Top-up Vendor to independent professional, institutional and/or individual investors to be procured by the Placing Agent under the Placing and Subscription Agreement
“%”	per cent

In this announcement, the terms “associate”, “connected person”, “controlling shareholder” and “substantial shareholder” have the meanings given to such terms in the Listing Rules, unless the context otherwise requires.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, February 3, 2023

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman and executive Director and Ms. LIU Yang as executive Director, Mr. XU Zhan Kevin as non-executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as independent non-executive Directors.